Trial Profile

A Phase 2 Study of Alisertib in Combination With Endocrine Therapy in Patients With HR+, HER2-negative Recurrent or Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alisertib (Primary) ; Anastrozole; Antineoplastics; Exemestane; Fulvestrant; Letrozole; Tamoxifen
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ALISCA-Breast1
Sponsors Puma Biotechnology

Most Recent Events

26 Feb 2026 According to a Puma Biotechnology media release, presentation of interim data from this trial is Q2 2026.
06 Nov 2025 According to a Puma Biotechnology media release, company anticipates interim data from this trial over the next 12 months/H12026.
20 Nov 2024 According to a Puma Biotechnology media release, initial data from this trial is anticipated in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com